Everything below concerns purity testing. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-04-08. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Synonyms | SR9009; Stenabolic | Stenabolic is an informal name |
| Common form | Crystalline powder | Supplied in milligram to gram quantities |
| Long-term storage | -20 °C, desiccated, protected from light | Reduces degradation |
| Detection technique | LC-MS/MS | Common in anti-doping and research analysis |
| Regulatory status | Prohibited in sport by WADA | Not approved for human therapeutic use |
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
I am left with the impression that the attorneys in charge of the Labscam investigation ... seek to take far more credit for the overall success of the proceedings than is rightly due. Philadelphia-based SmithKline agreed to pay the government $325 million which is considered as one of the largest civil settlement ever in a whistle-blower lawsuit. The company settled after the government alleged it paid kickbacks to doctors, billed the government for laboratory tests not performed and committed other violations. SmithKline has denied the allegations, saying the violations were unintentional and the result of ambiguities in regulations and guidelines. When interest and payments to state Medicare funds were taken into account, the final settlement came to about $321 million. VanArtsdalen said Merena and the other whistle-blowers accounted for all but about $15 million of that total. The government failed to reach an agreement with litigants Merena and Grossenbacher on the amount that they would receive from the settlement agreement. The government maintained that Merena was entitled to approximately $10 million of the $65 million attributable to the non-"automated chemistry" claims and has paid Merena this amount. The government and the Spear relators have a proposed agreement that, if approved, will award the Spear relators 15% of the $13 million that the government attributed to a claim called the "CBC Indices" claim. The government previously agreed to pay the whistle-blowers a minimum of $9.7 million but only if they dropped claims to a larger portion.
== Algorithms == Several algorithms have been developed specifically for the protein design problem. These algorithms can be divided into two broad classes: exact algorithms, such as dead-end elimination, that lack runtime guarantees but guarantee the quality of the solution; and heuristic algorithms, such as Monte Carlo, that are faster than exact algorithms but have no guarantees on the optimality of the results. Exact algorithms guarantee that the optimization process produced the optimal according to the protein design model. Thus, if the predictions of exact algorithms fail when these are experimentally validated, then the source of error can be attributed to the energy function, the allowed flexibility, the sequence space or the target structure (e.g., if it cannot be designed for). Some protein design algorithms are listed below. Although these algorithms address only the most basic formulation of the protein design problem, Equation (1), when the optimization goal changes because designers introduce improvements and extensions to the protein design model, such as improvements to the structural flexibility allowed (e.g., protein backbone flexibility) or including sophisticated energy terms, many of the extensions on protein design that improve modeling are built atop these algorithms. For example, Rosetta Design incorporates sophisticated energy terms, and backbone flexibility using Monte Carlo as the underlying optimizing algorithm. OSPREY's algorithms build on the dead-end elimination algorithm and A* to incorporate continuous backbone and side-chain movements.
== History == Loperamide hydrochloride was first synthesized in 1969 by Paul Janssen from Janssen Pharmaceuticals in Beerse, Belgium, following previous discoveries of diphenoxylate hydrochloride (1956) and fentanyl citrate (1960). The first clinical reports on loperamide were published in 1973 with the inventor being one of the authors. The trial name for it was "R-18553". Loperamide oxide has a different research code: R-58425. The trial against placebo was conducted from December 1972 to February 1974, its results being published in 1977. In 1973, Janssen started to promote loperamide under the brand name Imodium. In December 1976, Imodium got US FDA approval. During the 1980s, Imodium became the best-selling prescription antidiarrheal in the United States. In March 1988, McNeil Pharmaceutical began selling loperamide as an over-the-counter drug under the brand name Imodium A-D. In the 1980s, loperamide also existed in the form of drops (Imodium Drops) and syrup. Initially, it was intended for children's usage, but Johnson & Johnson voluntarily withdrew it from the market in 1990 after 18 cases of paralytic ileus (resulting in six deaths) were registered in Pakistan and reported by the World Health Organization (WHO). In the following years (1990-1991), products containing loperamide have been restricted for children's use in several countries (ranging from two to five years of age). In the 1980s, before the US patent expired on 30 January 1990, McNeil started to develop Imodium Advanced containing loperamide and simethicone for treating both diarrhea and gas.
After Protestantism, individuals professing no religion are also a significant group, having exceeded 8% of the population according to the 2010 census. The cities of Boa Vista, Salvador, and Porto Velho have the greatest proportion of Irreligious residents in Brazil. Teresina, Fortaleza, and Florianópolis were the most Roman Catholic in the country. Greater Rio de Janeiro, not including the city proper, is the most irreligious and least Roman Catholic Brazilian periphery, while Greater Porto Alegre and Greater Fortaleza are on the opposite sides of the lists, respectively. In October 2009, the Brazilian Senate approved, and enacted by the President of Brazil in February 2010, an agreement with the Vatican, in which the Legal Statute of the Catholic Church in Brazil is recognized.
=== Developmental factors === Various developmental factors may affect rates of obesity. Breastfeeding, for example, may protect against obesity in later life with the duration of breastfeeding inversely associated with the risk of being overweight later on. A child's body growth pattern may influence the tendency to gain weight. Researchers measured the standard deviation (SD [weight and length]) scores in a cohort study of 848 babies. They found that infants who had an SD score above 0.67 had catch up growth (they were less likely to be overweight) compared to infants who had less than a 0.67 SD score (they were more likely to gain weight). Additionally, breastfeeding for less than six months, compared to six months or more, has been shown to result in a higher growth rate and higher BMI at 18, 36, and 72 months of age. A child's weight may be influenced when he/she is only an infant. Researchers also did a cohort study on 19,397 babies from their birth until age seven and discovered that high-weight babies at four months were 1.38 times more likely to be overweight at seven years old compared to normal-weight babies. High-weight babies at the age of one were 1.17 times more likely to be overweight at age seven compared to normal-weight babies.
Sources: en.wikipedia.org
=== Hypothalamic–hypophyseal portal system === Dopamine released at TIDA terminals enters the long portal veins and is delivered directly to lactotrophs of the anterior pituitary. An additional source of dopamine reaches the anterior lobe from the neurointermediate lobe via short portal vessels. Severing or compressing the pituitary stalk eliminates dopamine delivery and causes prolactin levels to rise sharply, an effect opposite to that seen with every other anterior pituitary hormone.
Before 1957, the Union of South Africa had relied on small standing cadres for defence, expanding during wartime through the use of white conscripts. During the Second World War the Union Defence Force initially fielded only 3,353 full-time soldiers, with another 14,631 active in reserve roles. These troops were not prepared to fight in Europe proper, as they had hitherto been trained only in basic light infantry tactics and bush warfare. However, Jan Christiaan Smuts proved remarkably resourceful in raising 345,049 men for overseas operations; South African soldiers went on to distinguish themselves as far abroad as Italy and Egypt.
== Biosynthesis == GGC is synthesized from L-glutamic acid and L-cysteine in the cytoplasm of virtually all cells in an adenosine triphosphate (ATP)-requiring reaction catalyzed by the enzyme glutamate-cysteine ligase (GCL, EC 6.3.2.2; formerly γ-glutamylcysteine synthetase). The production of GGC is the rate limiting step in glutathione synthesis.
TGFK-09SD, or TGFK09SD, is a serotonin 5-HT1A receptor agonist which is or was under development for the treatment of female sexual dysfunction but was never marketed. It is taken orally. The drug was developed by Fabre-Kramer Pharmaceuticals. As of January 2016, it is in phase 2 clinical trials. There have been no further updates on the development of the drug since then. The chemical structure of TGFK-09SD does not yet appear to have been disclosed.
Sources: en.wikipedia.org
German literature can be traced back to the Middle Ages and the works of writers such as Walther von der Vogelweide and Wolfram von Eschenbach. Well-known German authors include Johann Wolfgang von Goethe, Friedrich Schiller, Gotthold Ephraim Lessing and Theodor Fontane. The collections of folk tales published by the Brothers Grimm popularised German folklore on an international level. The Grimms also gathered and codified regional variants of the German language, grounding their work in historical principles; their Deutsches Wörterbuch, or German Dictionary, sometimes called the Grimm dictionary, was begun in 1838 and the first volumes published in 1854. Influential authors of the 20th century include Gerhart Hauptmann, Thomas Mann, Hermann Hesse, Heinrich Böll, and Günter Grass. The German book market is the third-largest in the world, after the United States and China. The Frankfurt Book Fair is the most important in the world for international deals and trading, with a tradition spanning over 500 years. The Leipzig Book Fair also retains a major position in Europe.
Based upon the available area of nasal skin, the surgeon selects the locale for the bilobed flap, and orients the pedicle. If the defect is in the lateral aspect of the nose, the pedicle is based medially. If the defect is at the nasal tip, or at the nasal dorsum, the pedicle is based laterally. An ideal location for the second flap is along the junction of the nasal dorsum and the lateral nasal wall. The nasal wound is cut and shaped into a teardrop form, by the cutting out of a Burrow's triangle of flesh on the side of pedicle base. Cutting out the Burrow's triangle (skin and subcutaneous fat) permits the moving the pedicle flap, to emplace it without buckling the tissues adjacent to the graft. Using a 20 mm calliper as a protractor—one tip at the apex of the wound—the surgeon delineates two semi-circles, an inner semi-circle, and an outer semi-circle. The outer semi-circle defines the necessary length of the two lobes of the skin flap. The inner semi-circle bisects the center of the original wound, and continues across the donor skin, establishing limit measure of the pedicle common to the two lobes of the flap. The surgeon then draws two lines from the apex of the wound; the first line drawn is at an angle of 45 degrees from the long axis of the wound, and the second line drawn is at a 90-degree angle from the axis of the wound. The two lines delineate the central axes of the two lobes of the bilobed flap.
The enzyme characterised from Aspergillus niger and mammalian liver hydrolyses nicotinamide to nicotinic acid and ammonia. This reaction is part of the salvage pathway for nicotinamide adenine dinucleotide. Inhibition of the enzyme has been suggested as a mechanism of insect control. The prodrug, pyrazinamide, is converted into the bacteriostatic pyrazinoic acid by this enzyme in Mycobacterium tuberculosis. This enzyme is a hydrolase, one acting on carbon-nitrogen bonds other than peptide bonds, specifically in linear amides. The systematic name of this enzyme class is nicotinamide amidohydrolase. Other names in common use include nicotinamide deaminase, nicotinamide amidase, and YNDase.
Sources: en.wikipedia.org
Laboratories commonly use liquid chromatography coupled with mass spectrometry to detect SR9009. The method can identify the compound and estimate concentration in a sample. Detection limits depend on the matrix and instrument.
Research-grade purity indicates a supplier's measured percentage of the intended compound. It does not guarantee safety, sterility, or suitability for human consumption. Buyers should request a certificate of analysis with chromatograms and test methods.
Sports regulators prohibit SR9009 because it is a non-approved substance with potential performance-altering effects. Its presence can be detected in anti-doping testing. Athletes are responsible for substances found in their samples.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.